Aviragen Therapeutics Company Profile (NASDAQ:NABI)

About Aviragen Therapeutics (NASDAQ:NABI)

Aviragen Therapeutics logoAviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Industry, Sector and Symbol:
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -5,900.00%
  • Return on Equity: -110.33%
  • Return on Assets: -54.53%
 

Frequently Asked Questions for Aviragen Therapeutics (NASDAQ:NABI)

What is Aviragen Therapeutics' stock symbol?

Aviragen Therapeutics trades on the NASDAQ under the ticker symbol "NABI."

Who are some of Aviragen Therapeutics' key competitors?

Who are Aviragen Therapeutics' key executives?

Aviragen Therapeutics' management team includes the folowing people:

  • Mark P. Colonnese, Chief Financial Officer, Executive Vice President
  • Russell H. Plumb, Executive Chairman of the Board
  • Joseph M. Patti Ph.D., President, Chief Executive Officer, Director
  • Armando Anido, Independent Director
  • Geoffrey F. Cox Ph.D., Independent Director
  • Michael R. Dougherty, Independent Director
  • Michael W. Dunne M.D., Independent Director
  • John P. Richard, Independent Director

How do I buy Aviragen Therapeutics stock?

Shares of Aviragen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Aviragen Therapeutics (NASDAQ NABI)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  27 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about Aviragen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aviragen Therapeutics (NASDAQ:NABI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Aviragen Therapeutics (NASDAQ:NABI)
Price Target History for Aviragen Therapeutics (NASDAQ:NABI)
Analysts' Ratings History for Aviragen Therapeutics (NASDAQ:NABI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Aviragen Therapeutics (NASDAQ:NABI)
Earnings by Quarter for Aviragen Therapeutics (NASDAQ:NABI)
Earnings History by Quarter for Aviragen Therapeutics (NASDAQ NABI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2012Q312($0.12)$1.10 millionViewN/AView Earnings Details
11/2/2011($0.09)($0.07)ViewN/AView Earnings Details
8/3/2011($0.23)($0.11)ViewN/AView Earnings Details
5/5/2011($0.18)$0.05ViewN/AView Earnings Details
3/8/2011($0.08)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aviragen Therapeutics (NASDAQ:NABI)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aviragen Therapeutics (NASDAQ:NABI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aviragen Therapeutics (NASDAQ:NABI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Aviragen Therapeutics (NASDAQ:NABI)
Latest Headlines for Aviragen Therapeutics (NASDAQ:NABI)
Source:
No headlines for this company have been tracked by MarketBeat.com

Social

Chart

Aviragen Therapeutics (NABI) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.